CG Oncology (CGON) Receivables (2023 - 2026)
CG Oncology (CGON) reported Receivables of $1.3 million for Q1 2026, up 269.57% on a YoY basis from $345000.0 in Q1 2025, and up 85.32% quarter-over-quarter from $688000.0 in Q4 2025.
CG Oncology (CGON) Receivables (2023 - 2026) Analysis & Trends
CG Oncology has reported Receivables for 4 years, with the latest figure at $1.3 million in Q1 2026.
- For the quarter ending Q1 2026, Receivables rose 269.57% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (up 269.57% YoY), and the FY2025 full-year result was $688000.0, changed N/A from the prior year.
- Receivables for Q1 2026 stood at $1.3 million, up from $688000.0 in the prior quarter.
- The five-year high for Receivables was $1.3 million in Q1 2026, with the low at $92000.0 in Q4 2023.
- Historically, Receivables has averaged $438777.8 across 4 years, with a median of $345000.0 in 2025.
- The largest YoY upside for Receivables was 275.91% in 2025 against a maximum downside of 125.49% in 2025.
- CG Oncology's Receivables stood at $92000.0 in 2023, then jumped by 48.91% to $137000.0 in 2024, then surged by 402.19% to $688000.0 in 2025, then jumped by 85.32% to $1.3 million in 2026.
- The last three Receivables figures came in at $1.3 million (Q1 2026), $688000.0 (Q4 2025), and $515000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 13.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 2.00 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | CG Oncology | 5.16 Bn | 5.16 Bn | -1.88 Mn | 1.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.28 Mn |
| Dec 31, 2025 | 688,000.00 |
| Sep 30, 2025 | 515,000.00 |
| Jun 30, 2025 | 562,000.00 |
| Mar 31, 2025 | 345,000.00 |
| Sep 30, 2024 | 137,000.00 |
| Jun 30, 2024 | 182,000.00 |
| Mar 31, 2024 | 153,000.00 |
| Dec 31, 2023 | 92,000.00 |